What is TB-500?
TB-500 is the laboratory name for a synthetic fragment of Thymosin Beta-4 (Tβ4) — specifically, the central actin-binding domain comprising amino acids 17–23 of the parent 43-residue protein. The full-length Tβ4 protein is one of the most abundant actin-sequestering peptides in mammalian cells; the synthetic fragment is the active core used in most published experimental work.
Like BPC-157, TB-500 is sold as a “research peptide” labelled for laboratory use only. It is not approved for human consumption outside specific regulatory approvals (none of which currently exist for TB-500 specifically; Tβ4 has had limited human trial work for wound healing indications).
Evidence snapshot
Status: Preclinical only (full-length Tβ4 has limited human trial data in specific indications). Studies referenced: 80+ for Tβ4, fewer for TB-500 fragment specifically. Regulatory approval: None for TB-500 in any jurisdiction.
Actin sequestration & cytoskeletal biology
The dominant mechanism of Tβ4 / TB-500 is sequestration of G-actin (monomeric globular actin). By binding monomeric actin in a 1:1 stoichiometry, Tβ4 prevents premature actin polymerisation and maintains a pool of unpolymerised actin available for rapid cytoskeletal remodelling.
This function is essential in cell types that need to reorganise their cytoskeleton quickly: motile cells (keratinocytes at wound edges, immune cells, cancer cells in metastasis), stem cells, and cells undergoing differentiation. Knockout of the TMSB4X gene (encoding Tβ4) is embryonically lethal in mice, underscoring the protein’s importance in development.
Cell migration & wound healing
Cell migration depends on coordinated actin polymerisation at the leading edge of the moving cell. Tβ4 promotes this process by maintaining a reservoir of actin monomers that can be deployed rapidly when the cell extends a lamellipodium or filopodium.
In wound-healing models, exogenous Tβ4 accelerates keratinocyte migration across the wound bed, enhances granulation tissue formation, and improves the organisation of collagen in the healing dermis. These observations have been replicated across multiple rodent and ex vivo human skin models.
Angiogenesis
Tβ4 / TB-500 promotes angiogenesis through several mechanisms, including upregulation of VEGF, hypoxia-inducible factor (HIF), and matrix metalloproteinase activity. In rodent hind-limb ischemia and myocardial infarction models, Tβ4 administration has been shown to increase capillary density and improve perfusion in the damaged tissue.
This pro-angiogenic activity overlaps with the mechanism of BPC-157, and is the most common mechanistic justification for studying the two compounds together.
Tissue-specific research
- Skin — accelerated wound closure, improved dermal collagen organisation, and reduced scar formation in rodent and porcine models.
- Cornea — improved epithelial healing and reduced inflammation in corneal wound models. Tβ4 has been investigated in clinical trials for dry-eye disease under the name rythmavus.
- Heart — improved cardiac function and reduced fibrosis in rodent post-MI models, attributed partly to epicardial progenitor cell activation.
- Nervous system — modest neuroprotective effects in stroke and traumatic brain injury models, with proposed mechanisms involving anti-inflammatory and anti-apoptotic effects.
- Hair follicle cycling — Tβ4 promotes hair growth in mouse models by stimulating stem cell migration and follicle cycling. The magnitude of effect in human androgenetic alopecia is unknown.
Limits of the evidence
Most published work uses the full-length Tβ4 protein rather than the TB-500 fragment specifically. The fragment retains the actin-binding domain but loses the G-actin reservoir capacity of the full-length protein; its pharmacology is therefore not interchangeable with Tβ4 itself.
Other limitations:
- No large human RCTs of TB-500. Limited human data exists for Tβ4 in specific ophthalmic and dermatology indications.
- Concentration variability. Preclinical studies use widely varying doses, often in the 1–1000 μg/kg range, with no consensus.
- Off-label use in sport. TB-500 is widely used off-label in horse racing (where it was a target of early anti-doping work) and human athletic contexts. WADA classifies TB-500 as a prohibited substance.
- Mechanism redundancy. Multiple actin-binding proteins exist; Tβ4 is one of several. Genetic redundancy and compensatory mechanisms in vivo complicate interpretation.
Regulatory status
TB-500 is not approved for human use by the FDA, EMA, or MHRA. It is on the FDA peptide watch-list and is classified by WADA as a prohibited substance in athletic competition. The full-length Tβ4 protein has had investigational new-drug (IND) status in past human trials but is not currently an approved therapeutic.
The bottom line
The Tβ4 / TB-500 mechanism story is well-supported at the molecular level, and the preclinical wound-healing literature is consistent. The translation to therapeutic efficacy in humans is much less clear, and the synthetic TB-500 fragment has been studied less extensively than the parent protein.